Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PGK1 | P00558 | 6/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173830 | 0.86 | STING1 (0.48) | NPC1RAB9AKMT2APGK1ALOX15 | |
| SCHEMBL21395441 | 0.81 | NPC1 (0.46) | NPC1RAB9AKMT2APGK1GSK3B | |
| SCHEMBL14970154 | 0.81 | ALOX15 (0.62) | NPC1RAB9AKMT2APGK1GSK3B | |
| SCHEMBL7679151 | 0.80 | CYP3A4 (0.53) | NPC1RAB9AKMT2APGK1GSK3B | |
| SCHEMBL29741763 | 0.80 | CYP3A4 (0.53) | NPC1RAB9AKMT2APGK1GSK3B | |
| SCHEMBL3089621 | 0.80 | SMN1; SMN2 (0.35) | NPC1RAB9AKMT2AATMGAA | |
| SCHEMBL10220044 | 0.78 | NPC1 (0.44) | NPC1RAB9AKMT2APGK1GSK3B | |
| SCHEMBL10271517 | 0.78 | NPC1 (0.61) | NPC1RAB9AKMT2APGK1GSK3B | |
| SCHEMBL12312873 | 0.76 | PGK1 (0.47) | NPC1RAB9AKMT2APGK1GSK3B | |
| SCHEMBL21091211 | 0.73 | CYP3A4 (0.53) | NPC1RAB9APGK1GSK3BMAP4K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1205472-B1 | Process for the preparation of dithiazolyldisulfides | BAYER AG (DE) | 2005-01-26 | — | — | EP | disclosed |
| US-6610857-B2 | Oxidation of 2-mercaptothiazoles with peroxidic compounds in an aqueous suspension | BAYER AKTIENGESELLSCHAFT (DE) | 2003-08-26 | — | — | US | disclosed |
| EP-1205472-A1 | Process for the preparation of dithiazolyldisulfides | BAYER AG (DE) | 2002-05-15 | — | — | EP | disclosed |
| US-20020055640-A1 | Process for the production of dithiazolyl disulfides | LANXESS DEUTSCHLAND GMBH (DE) | 2002-05-09 | — | — | US | disclosed |
| US-6248896-B1 | APPROPRIATELY SUBSTITUTED 2-MERCAPTOTHIAZOLE IS OXIDIZED WITH OXYGEN OR AN OXYGEN-CONTAINING GAS IN THE PRESENCE OF A SOLVENT AND A TERTIARY AMINE AND IRON HEMIPORPHYRAZINE. | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-19 | — | — | US | disclosed |
| US-6124467-A | Process for the preparation of dithiazolyl disulfides | BAYER AKTIENGESELLSCHAFT (DE) | 2000-09-26 | — | — | US | disclosed |
| EP-1008591-A1 | Process for the preparation of dithiazolyldisulfides | Bayer Aktiengesellschaft (DE) | 2000-06-14 | — | — | EP | disclosed |
| US-5436346-A | Process for the preparation of benzothiazolyl-2-sulphenamides | AKZO NOBEL N.V. (NL) | 1995-07-25 | — | — | US | disclosed |
| US-5124450-A | Reacting solution of 2-mercaptothiazole, saturated secondary heterocyclic amine, sulfur in presence of oxygen, ammonia, copper or cerium catalyst | AKZO N.V. (NL) | 1992-06-23 | — | — | US | disclosed |
| EP-0481366-A1 | Process for the preparation of 2-Aminodithiothiazoles and 2-Aminotrithiothiazoles | Akzo Nobel N.V. (NL) | 1992-04-22 | — | — | EP | disclosed |
| EP-0131776-B1 | PROCESS FOR THE PREPARATION OF THIAZOLE-2-SULFENAMIDES | Akzo Patente GmbH (DE) | 1990-02-28 | — | — | EP | disclosed |
| US-4670556-A | BY-PRODUCT INHIBITION | AKZO NV (NL) | 1987-06-02 | — | — | US | disclosed |
| US-4558135-A | AMMONIA CATALYST | AKZONA INCORPORATED (US) | 1985-12-10 | — | — | US | disclosed |
| EP-0131776-A2 | Process for the preparation of thiazole-2-sulfenamides | Akzo Patente GmbH (DE) | 1985-01-23 | — | — | EP | disclosed |
| US-4307236-A | BY CATALYTIC OXIDATION OF 2-MERCAPTO THIAZOLES | AKZONA INCORPORATED (US) | 1981-12-22 | — | — | US | disclosed |
| US-4182873-A | AMINATION OF MERCAPTO THIAZOLE OR DISULFIDE | RHONE-POULENC S.A. (FR) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055640-A1 | Process for the production of dithiazolyl disulfides | GPX4, PRDX3, PRDX2 | NPC1 4281/4885RAB9A 4533/4885KMT2A 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.